ClinicalTrials.gg
Not yet recruitingNCT06510530Updated Sep 30, 2026

Astragalus for Symptomatic Alleviation in High-grade Lymphoma

A Phase 3 interventional study of Astragalus and Placebo in High-grade Lymphoma, sponsored by Bnai Zion Medical Center. Not yet recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Bnai Zion Medical Center · Phase 3, Interventional, and Prevention

Updated Sep 30, 2026Start date movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies in Lymphoma, Non-Hodgkin with a site in Israel — 7 open to participants now, 28 under way, 11 of them phase 3. Lymphoma, Non-Hodgkin · Israel.

Planned enrollment
58th of 76
60 · median 157
Started
2027
the only one that year
Phase 3
26 of 79
2 open now
Primary completion
2030-08
later than 25 of 27 live
Registered
76th of 79
by date

Among the 79 studies in Lymphoma, Non-Hodgkin with a site in Israel, this one is the 58th largest by planned enrollment of the 76 interventional ones that give a count, is the only one that started in 2027, is one of 26 in phase 3, reaches primary completion later than 25 of the 27 other live ones, and was the 76th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

7 of the 79 studies in Lymphoma, Non-Hodgkin with a site in Israel are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Lymphoma, Non-Hodgkin with a site in Israel, or all of them as a file.
02

Study summary

Lymphoma is a malignant disease of the lymph nodes. There are different types of lymphoma: when some of the lymphomas are indolent and require only follow-up, in cases of aggressive lymphoma or indolent lymphoma with a burden of disease, treatment is necessary, which usually includes chemotherapy with or without biological drugs. These drugs often cause significant damage to the quality of life, various symptoms including exhaustion, neuropathic pain, nausea/vomiting, cognitive decline, as well as a drop in blood counts with serious life-threatening infections that cause a delay in the treatment date that may affect the prognosis.

Drug treatments for symptomatic relief and improvement in quality of life in patients with lymphoma are missing, with only a partial effect and involving side effects.

Astragalus (scientific name: Astragalus membranaceus, common name: Huang Qi) is a perennial flowering plant common in China with a long history of use in traditional Chinese medicine. It is given in various forms of root in combination with other herbs, medicinal soups and as tablets, capsules, solutions, ointments for local use, or subcutaneous or intravenous injection. In patients with oncological diseases, a systematic review (4 trials on a total of 342 patients) showed an improvement in nausea and vomiting as well as in the immune system in patients with colon cancer who received Chemotherapy. A meta-analysis of 27 studies on 1,843 patients with colon cancer also demonstrated a reduction in chemotherapy-induced nausea in patients who received a combination of astragalus with chemotherapy compared to chemotherapy alone. In another meta-analysis that included 45 trials on 3,236 patients with liver cancer, an improvement in 12-month survival was reported with products containing astragalus. In a randomized study of 136 patients with lung cancer, three treatment cycles with astragalus by injection in combination with chemotherapy (vinorelbine and cisplatin) resulted in a significant improvement in quality of life compared to the control group that received chemotherapy alone. Similar results found in 23 patients with metastatic malignancy receiving astragalus by injection in combination with chemotherapy. In addition, a study on 90 patients with advanced cancer showed an improvement in fatigue in patients who received astragalus. Also, a pilot study on 60 patients with breast cancer showed that intravenous administration of astragalus improved blood counts in patients who received it in combination with chemotherapy compared to chemotherapy alone. In patients with hematological malignancies, a study was conducted on 498 patients with acute myeloid leukemia and showed that the use of astragalus or plants containing astragalus was associated with improved survival compared to patients who did not receive it. In the context of lymphoma, a pharmacological study in vivo on animals with lymphoma showed that a combination of an astragalus-containing formula with adriamycin-type chemotherapy improved the effect of adriamycin for the treatment of B-cell lymphoma. Another study in patients who had completed conventional chemotherapy with Rituximab Cyclophosphamide Adriamycine Vincristine Prednisone (R-CHOP) for diffuse large B-cell lymphoma showed that administration of a formula containing astragalus improved immune function and blood counts. Finally, a randomized placebo-controlled study showed that giving a formula containing astragalus to patients under R-CHOP chemo-immunotherapy as first line for diffuse large B cell lymphoma high risk significantly reduced the appearance of side effects from the treatment and improved response to the treatment chemotherapy compared to the control group.

Side effects attributed to astragalus include fatigue, weakness, headaches and hypotension, but in the cited studies and meta-analyses, no increase in the rate of side effects was found in the groups of patients who received this plant compared to the control groups, and no safety problems were described in the use of astragalus in combination with chemotherapy.

In light of the multitude of symptoms that affect the quality of life and adherence to treatment in patients with lymphoma receiving chemotherapy, and in light of the encouraging findings in the literature about symptomatic improvement as a result of combining astragalus during chemotherapy in various malignancies, the investigators aim to examine the effectiveness and safety of astragalus during the treatment of patients with high-grade lymphoma on symptomatic relief and adherence to chemotherapy in a randomized, double-blind, placebo-controlled study.

03

Conditions studied

  • High-grade Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18
  • Diagnosis of high-grade lymphoma
  • Need to start treatment for lymphoma that includes chemotherapy as
  • Possibility to answer questionnaires once a month
  • Signing an form

Exclusion criteria

Exclusion Criteria:

  • Taking up to a week before the randomization a drug with the potential for an interaction of major clinical significance with Astragalus according to a professional database
  • Administration of chemotherapy in the past
  • Significant disturbance in liver enzymes: and/or alanine transaminase above 5 times the
  • Significant renal dysfunction: under 30 ml/min according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  • Active disease
  • Pregnancy or breastfeeding
  • Active participation in another interventional study
  • Psychiatric disorder with impaired cognitive qualifications
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Astragalus

    Dietary Supplement: Astragalus

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementAstragalus

    Patients in the intervention group will receive capsules of the Astragalus plant (scientific name: Astragalus membranaceus, common name: Huang Qi) at an initial dose of 2 grams (4 capsules) per day with the option of increasing the dose to 4 grams (8 capsules) per day according to researchers' assessment and patient tolerance. The dose was determined by a focus group of 5 herbalists and according to data from the literature on oncology patients. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.

  • Dietary supplementPlacebo

    Placebo capsules that look similar to Astragalus capsules will be given to patients from the control group, between 4 and 8 capsules per day according to the researcher's assessment and tolerability. The duration of the treatment will be up to a month from the end of the chemotherapy treatment which usually lasts up to six months.

06

What researchers measure

Primary outcomes

  1. Quality-of-life

    European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire summary score which is calculated from the mean of 13 of the 15 quality-of-life (QLQ-C30) scales of the questionnaire = (Physical Functioning+ Role Functioning+ Social Functioning+ Emotional Functioning+ Cognitive Functioning+ 100-Fatigue+ 100-Pain+ 100-Nausea\_Vomiting+ 100-Dyspnoea+ 100-Sleeping Disturbances+ 100-Appetite Loss+ 100-Constipation+ 100-Diarrhoea)/13. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.

    Time frame: From baseline to end-of-treatment, up to 6 months

Secondary outcomes

  1. Symptoms

    Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire at end of treatment: two main concerns of the patient which are rated for severity using a simple numerical Likert scale 0-6 (0: not concerning at all; 6: very concerning).

    Time frame: From baseline to end-of-treatment, up to 6 months

  2. Fatigue

    European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire fatigue score. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("worse") level of fatigue.

    Time frame: From baseline to end-of-treatment, up to 6 months

Other outcomes

  1. Nausea and vomiting

    European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire nausea\&vomiting score. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("worse") level of nausea and vomiting.

    Time frame: From baseline to end-of-treatment, up to 6 months

  2. Cognitive function

    European Organization Research for Treatment of cancer core quality of life (EORTC-QLQ-C30) questionnaire cognitive functioning score. Scores range from minimum 0 to maximum 100; a higher score represents a higher ("better") level of cognitive functioning.

    Time frame: From baseline to end-of-treatment, up to 6 months

  3. Severe neutropenia

    Frequency of severe neutropenia episodes defined as absolute neutrophil count under 0.5x10\^9/L

    Time frame: Evaluated at day 10-13 of each cycle (each cycle is 14-28 days depending on chemotherapy protocol) during the study treatment (up to 6 months)

  4. Packed cells transfusion

    Frequency of packed cells transfusion during the study treatment

    Time frame: Through the study treatment, up to 6 months

  5. Use of Granulocyte colony stimulating factors (G-CSF)

    Frequency of G-CSF use during the study treatment

    Time frame: Through the study treatment, up to 6 months

  6. Infections

    Frequency of infections during the study treatment

    Time frame: Through the study treatment, up to 6 months

  7. Hospitalizations

    Frequency of hospitalizations during the study treatment

    Time frame: Through the study treatment, up to 6 months

  8. Compliance to chemotherapy

    Relative dose intensity (RDI) which is the ratio of delivered dose intensity (DDI) of chemotherapy with standard dose intensity (SDI) of chemotherapy = DDI/SDI

    Time frame: Through the study treatment, up to 6 months

  9. Overall response rate (ORR)

    Percentage of patients who have a partial response or complete response to the treatment of lymphoma

    Time frame: Through the study treatment, up to 6 months

  10. Complete response (CR) rate

    Percentage of patients who have a complete response to the treatment of lymphoma

    Time frame: Through the study treatment, up to 6 months

  11. Progression-free survival (PFS)

    The length of time during and after the treatment of lymphoma (first line) that patient lives and disease does not progress

    Time frame: Up to 2 years after end-of-study treatment: up to 2.5 years

  12. Overall survival (OS)

    The length of time during and after the treatment of lymphoma (first line) that patient lives

    Time frame: Up to 2 years after end-of-study treatment: up to 2.5 years

  13. Incidence of Treatment-Emergent Adverse Events

    According to report of adverse events, severe adverse events, drug interactions

    Time frame: Through the study treatment, up to 6 months

  14. Economic analysis

    Calculation of quality-adjusted life years based on EuroQol-5 Dimension (EQ-5D) scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient indicates health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ visual analogue scale (VAS) records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: Through the study treatment, up to 6 months

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2027; primary completion for Aug 2030, 36 months later.

Of 58 phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 86. This study's planned 36 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2024 → Aug 2027, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2024
First posted
Jul 19, 2024
StartEst.
Aug 2027was Aug 2024
Primary completionEst.
Aug 2030
CompletionEst.
Aug 2032
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2024→Aug 2027
Sep 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionQuality-of-life: how it is measured was reworded
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Aug 2024→Aug 2027
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionQuality-of-life: how it is measured was reworded
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06510530
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Aug 2027 (estimated)
Primary completion
Aug 2030 (estimated)
Completion
Aug 2032 (estimated)
Last update
Sep 30, 2026

Study contacts

Ilana Levy Yurkovski, MD
Contact
ilana.e.levy@gmail.com
0525086128 ext. 972
Ilana Levy Yurkovski, MD
principal investigator · Bnai Zion Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion